- Home
- NAMS vs RNA Comparison
NAMS vs RNA Comparison
Compare NAMS & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | RNA |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAMS | RNA |
|---|---|---|
| Price | $32.21 | $72.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $46.40 | ★ $69.26 |
| AVG Volume (30 Days) | 764.0K | ★ 1.9M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,243,000.00 | $20,868,000.00 |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $10.46 | $18.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.91 | ★ 106.27 |
| 52 Week Low | $14.06 | $21.51 |
| 52 Week High | $42.00 | $72.70 |
Technical Indicators
Market Signals| Indicator | NAMS | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 70.04 |
| Support Level | $30.97 | $72.23 |
| Resistance Level | $32.45 | $72.70 |
| Average True Range (ATR) | 1.64 | 0.17 |
| MACD | -0.24 | -0.14 |
| Stochastic Oscillator | 29.97 | 65.00 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.